Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206079 | 0.93 | OPRM1 (0.54) | OPRM1OPRL1EPHX2EPHX1 | |
| SCHEMBL4072325 | 0.91 | OPRM1 (0.52) | OPRM1OPRL1EPHX2EPHX1 | |
| SCHEMBL2976452 | 0.90 | MEN1 (0.46) | OPRM1OPRL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2982804 | 0.89 | CYP1A2 (0.42) | OPRM1OPRL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2989386 | 0.89 | LMNA (0.45) | EPHX1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2987319 | 0.89 | MEN1 (0.47) | OPRM1OPRL1EPHX2 | |
| SCHEMBL2983741 | 0.88 | SIGMAR1 (0.41) | OPRM1OPRL1 | |
| SCHEMBL2977995 | 0.88 | THRB (0.48) | OPRM1OPRL1EPHX2HPGD | |
| SCHEMBL2987110 | 0.86 | MEN1 (0.51) | OPRM1OPRL1EPHX2EPHX1 | |
| SCHEMBL2989227 | 0.85 | BCHE (0.41) | OPRM1OPRL1KCNA3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | claimed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | claimed |
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | DPYD, PKD1, AOC1 | OPRM1 1483/4885OPRL1 1292/4885EPHX2 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.